

Edgar Filing: OCEAN BIO CHEM INC - Form 8-K

OCEAN BIO CHEM INC  
Form 8-K  
August 18, 2009

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reportedly): August 18, 2009

OCEAN BIO-CHEM, INC.  
(Exact name of registrant as specified in charter)

Florida	0-11102	59-1564329
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

4041 S.W. 47 Avenue, Fort Lauderdale, Florida 33314  
(Address of principal executive office Zip Code)

(954) 587-6280

Registrant's telephone number, including area code:

Not Applicable  
(Former name or former address, if changes since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD - On August 14, 2009 the Company received a notice from the NASDAQ stock market (NASDAQ), that that its common stock has been at, or in excess of, \$1.00 per share for at least 10 consecutive business days. Accordingly, the Company has regained compliance with Listing Rule 5550(a) (2) of the Nasdaq Stock Market.

This notification closes the Nasdaq matter of non compliance for maintaining a minimum bid price of \$1.00 over the previous 30 consecutive business days, as required by the Listing Rules of The Nasdaq Stock Market.

Edgar Filing: OCEAN BIO CHEM INC - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Ocean Bio-Chem, Inc.

August 18, 2009

/s/ Jeffrey S. Barocas  
Jeffrey S. Barocas  
Vice President - Finance and  
Chief Financial Officer